Ovarian Cancer

  • Serah Choi
  • I-Chow J. HsuEmail author


This chapter will discuss the epidemiology, workup, staging, treatment recommendations, key studies, and radiation treatment techniques for ovarian cancer.


Ovarian cancer Ovarian carcinoma Whole abdominal irradiation and whole abdominal radiation therapy 



We thank R. Scott Bermudez MD, James Rembert MD for their work on the prior edition of this chapter.


  1. Alektiar KM, Chi DS, Kauff ND, Fuks ZY. Cancer of the ovary. In: Leibel SA, Phillips TL, editors. Textbook of radiation oncology. 3rd ed. Philadelphia: Saunders; 2010. p. 1052–66.CrossRefGoogle Scholar
  2. Armstrong DK, Bundy B, Wenzel L, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med.2006;354:34–43.CrossRefGoogle Scholar
  3. Bell J, Brady MF, Young RC, et al. Randomized phase III trial of three versus six cycle of adjuvant carboplatin and paclitaxel in early stage epithelial ovarian carcinoma: a gynecologic oncology group study. Gyn Oncol. 2006;102:432–9.CrossRefGoogle Scholar
  4. Bundy B, Alberts DS, et al. Phase III trial of standard-dose intravenous Cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and Intraperitoneal Cisplatin in Small-Volume Stage III Ovarian Carcinoma: An Intergroup Study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Group. J Clin Oncol. 2001;19:1001–7.CrossRefGoogle Scholar
  5. Burger RA, Brady MF, Bookman MA, et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med. 2011;365(26):2473–83.CrossRefGoogle Scholar
  6. Chan JK, Brady MF, Penson RT, et al. Weekly vs. every-3-week paclitaxel and carboplatin for ovarian cancer. N Engl J Med. 2016;374(8):738–48.CrossRefGoogle Scholar
  7. Chiara S, Conte P, Franzone P, et al. High-risk early-stage ovarian cancer. Randomized clinical trial comparing cisplatin plus cyclophosphamide versus whole abdominal radiotherapy. Am J Clin Oncol. 1994;17(1):72–6.CrossRefGoogle Scholar
  8. Dembo AJ. Abdominopelvic radiotherapy in ovarian cancer. A 10-year experience. Cancer. 1985;55(9 Suppl):2285–90.CrossRefGoogle Scholar
  9. Edge SB, American Joint Committee on Cancer. American Cancer Society. AJCC cancer staging manual. 7th ed. New York: Springer Science+Business Media; 2010.Google Scholar
  10. Ferriss JS, Java JJ, Bookman MA, et al. Ascites predicts treatment benefit of bevacizumab in front-line therapy of advanced epithelial ovarian, fallopian tube and peritoneal cancers: an NRG oncology/GOG study. Gynecol Oncol. 2015;139(1):17–22.CrossRefGoogle Scholar
  11. Fyles AW, Dembo AJ, Bush RS, et al. Analysis of complications in patients treated with abdomino-pelvic radiation therapy for ovarian carcinoma. Int J Radiat Oncol Biol Phys. 1992;22(5):847–51.CrossRefGoogle Scholar
  12. Hoskins PJ, Le N, Gilks B, et al. Low-stage ovarian clear cell carcinoma: population-based outcomes in British Columbia, Canada, with evidence for a survival benefit as a result of irradiation. J Clin Oncol. 2012;30(14):1656–62.CrossRefGoogle Scholar
  13. ICON and EORTC-ACTION investigators. International collaboration on ovarian neoplasm trial 1 and adjuvant chemotherapy in ovarian neoplasm trial: two parallel randomized phase III trials of adjuvant chemotherapy in patients with early stage ovarian cancer. J Natl Cancer Inst. 2003;95:105–12.CrossRefGoogle Scholar
  14. Katsumata N, Yasuda M, Isonishi S, et al. Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial. Lancet Oncol. 2013;14(10):1020–6.CrossRefGoogle Scholar
  15. Kojs Z, Glinski B, Reinfuss M, et al. Results of a randomized prospective trial comparing postoperative abdominopelvic radiotherapy with postoperative chemotherapy in early ovarian cancer. Cancer Radiother. 2001;5:5–11.Google Scholar
  16. Lambert HE, Rustin GJ, Gregory WM, Nelstrop AE. A randomized trial comparing single-agent carboplatin with carboplatin followed by radiotherapy for advanced ovarian cancer: a North Thames Ovary Group study. J Clin Oncol. 1993;11(3):440–8.CrossRefGoogle Scholar
  17. Lee L, Berkowitz R, Matulonis U. Ovarian and fallopian tube cancer. In: Halperin CE, Wazer DE, Perez CA, Brady LW, editors. Principles and practice of radiation oncology. 6th ed. Philadelphia: Lippincott Williams & Wilkins; 2013. p. 1446–64.Google Scholar
  18. McGuire WP, Hosking WJ, Brady MF, et al. Taxol and cisplatin improves outcome in patients with advanced ovarian cancer as compared to cytoxan/cisplatin. N Engl J Med. 1996;334(1):1–6.CrossRefGoogle Scholar
  19. National Cancer Institute Surveillance, Epidemiology, and End Results Program (SEER). 2016. Accessed 20 Aug 2016.
  20. National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology: Ovarian Cancer (Version 1.2016). 2016. Available at: Accessed on 21 Aug 2016.
  21. Oza AM, Cook AD, Pfisterer J, et al. Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial. Lancet Oncol. 2015;16(8):928–36.CrossRefGoogle Scholar
  22. Ozols RF, Bundy BN, Greer E, et al. Phase III trials of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecology Oncology Group study. J Clin Oncol. 2003;21:3194–200.CrossRefGoogle Scholar
  23. Perren TJ, Swart AM, Pfisterer J, et al. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med. 2011;365(26):2484–96.CrossRefGoogle Scholar
  24. Piccart M, Bertelsen K, James K, et al. Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J Natl Cancer Inst. 2000;92:699–708.CrossRefGoogle Scholar
  25. Rochet N, Kieser M, Sterzing F, et al. Phase II study evaluating consolidation whole abdominal intensity-modulated radiotherapy (IMRT) in patients with advanced ovarian cancer stage FIGO III--the OVAR-IMRT-02 Study. BMC Cancer. 2011;11:41.Google Scholar
  26. Rochet N, Lindel K, Katayama S, et al. Intensity-modulated whole abdomen irradiation following adjuvant carboplatin/taxane chemotherapy for FIGO stage III ovarian cancer: four-year outcomes. Strahlenther Onkol. 2015;191:582-9.CrossRefGoogle Scholar
  27. Sorbe B. Consolidation treatment of advanced (FIGO stage III) ovarian carcinoma in complete surgical remission after induction chemotherapy: a randomized, controlled, clinical trial comparing whole abdominal radiotherapy, chemotherapy, and no further treatment. Int J Gynecol Cancer. 2003;13(3):278–86.CrossRefGoogle Scholar
  28. Swenerton KD, Santos JL, Gilks CB, et al. Histotype predicts the curative potential of radiotherapy: the example of ovarian cancers. Ann Oncol. 2011;22:341–7.CrossRefGoogle Scholar
  29. Vicus D, Small W Jr, Covens A. Ovarian cancer. In: Gunderson LL, Tepper JE, editors. Clinical radiation oncology. 4th ed. Philadelphia: Churchill Livingstone; 2015. p. 1264–1283.e5.Google Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of Radiation OncologyUniversity of California San FranciscoSan FranciscoUSA

Personalised recommendations